The FDA has stopped a clinical trial testing a Solid Biosciences gene therapy for Duchenne muscular dystrophy after a patient developed complications associated with the experimental treatment.
Cambridge, MA-based Solid Bio says the problems deemed to be related to the gene... Read more »
A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.
Roche announced... Read more »
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in... Read more »
[Updated 6:41 p.m. See below.] A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market.
The FDA on... Read more »
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »
Biotech startup eGenesis, which is applying gene editing to animal organs in order to make them suitable for human transplant, has raised $100 million to ramp up work on its kidney program and bring it into human testing.
The Series B... Read more »
The onset of one of the most devastating forms of dementia often comes with a misdiagnosis. Personality and behavioral changes in a patient can spark a hypothesis of depression or psychosis. Memory problems rouse suspicion of Alzheimer’s disease. By the... Read more »
When Mark Bakken formed the healthcare technology investment firm HealthX Ventures nearly five years ago, he says hospitals, insurers, and other potential buyers of digital health products were less open to conversations with the kinds of early-stage healthtech startups Bakken’s... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The move—which was announced at the China International... Read more »
Biogen is bolstering its strategy of selling biosimilars—lower-cost versions of biological drugs that are losing patent protection—with a $100 million deal for rights to two eye products. The drug maker is also expanding its biosimilar scope to include China.
Cambridge, MA-based... Read more »
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
The AstraZeneca (NYSE: AZN) site in Macclesfield,... Read more »
Section 32, which invests in healthcare and life sciences companies with a technology component, has added a third managing partner.
The small venture capital firm was started in San Diego about two years ago by Bill Maris, who, during his... Read more »